Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...

Get Instant Summarized Text (Gist) Early use of an intra-aortic balloon pump (IABP) in patients with cardiogenic shock due to heart failure did not improve 60-day survival or facilitate transition ...

Healthcare practitioners from around the world received hands-on training for treating patients in cardiogenic shock (CS) during a first-ever simulation lab at today's Annual Meeting and ...

Intra-aortic balloon pump did not outperform standard therapy in cardiogenic shock, with similar survival rates and adverse events. Tirzepatide reduced cardiovascular events and improved symptoms ...

The VASST trial was first published in 2008 and has spawned 16 years of analysis and debate. Aaron Holley, MD, has vacillated ...

(European Heart Journal) In heart failure complicated by cardiogenic shock, early intra-aortic balloon pump (IABP) placement did not help clinical outcomes in the small randomized trial Altshock-2.

According to reports, his death was caused by cardiogenic shock as a result of an acute myocardial infarction, or a severe heart attack. The reports further confirmed that the actor has been ...

Cardiogenic shock occurs when the heart is not able to pump enough blood to generate adequate cardiac output to maintain normal blood pressure. This frequently occurs in the setting of a large ...